Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

ons contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.VIVUS, Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited)Three Months EndedMarch 31March 3120112010Operating expenses:Research and development$
4,480$
,211General and administrative5,4285,164Total operating expenses9,90815,375Loss from operations(9,908)(15,375)Interest and other income (expense), net

42(1,233)Loss from continuing operations before income taxes(9,866)(16,608)Provision for income taxes(1)(1)Net loss from cont
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... BAX ) today announced data from PERSIST-1 – a ... treatment of myelofibrosis – in a late-breaking oral session ... Society of Clinical Oncology (ASCO), May 29-June 2, 2015 ... an investigational oral multikinase inhibitor with specificity for JAK2 ...
(Date:5/29/2015)... 2015 In recent years, the biopharmaceutical industry ... Data that can generate valuable insights. Despite this, the ... Data have caused the biopharmaceutical sector to embrace Big ... According to a recent study by benchmarking firm, ... Big Data team or function in place; however, these ...
(Date:5/29/2015)... May 29, 2015 Asthma ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading asthma ... fumarate) and Xolair (omalizumab), the global market for asthma ... end of the decade.   New analysis ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... human immune system isnt ready for a war. , ... illness, but they take time to work. A new ... Foundation (OMRF) and Emory University stands to revolutionize the ... Nature, the researchers describe a method that can identify ...
... GPRO ) announced today that the Company will present ... May 6 at approximately,11:30 a.m. Eastern Time. The presentation ... through a link on the investors section of Gen-Probe,s,website ... for 30,days following the event., About Gen-Probe, ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a provider ... results for Q1 2008. Q1 2008,revenues were $11.8 ... Q1 2008 revenues increased 5% in the ... its vascular category, while general,surgery revenues decreased 4%. ...
Cached Biology Technology:The most natural drug 2Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... the global pandemics of obesity and diabetes, poses a ... progress, there is still much to be done to ... In Europe, as many as one-half of patients are ... managing dyslipidaemias offer new hope.3,4 Experts from the European ...
... depends on the ability of the plant cover to intercept ... of leaf area, the architecture of the vegetation cover, and ... crop,s ability to capture light energy is the leaf area ... was defined as the ratio of leaf area to a ...
... cell that participates in the repair of the large airways ... the body from infectious agents and toxins in the environment. ... clearing mucus from the airways. The mucus is largely produced ... of normal and excessive mucus production are not well understood. ...
Cached Biology News:First joint ESC/EAS guidelines for the management of dyslipidaemias 2First joint ESC/EAS guidelines for the management of dyslipidaemias 3First joint ESC/EAS guidelines for the management of dyslipidaemias 4New non-destructive method to estimate leaf area index in vegetables 2UCLA stem cell scientists discover new airway stem cell 2
... ,,GenScript offers many antibody modification ... fragmentation. Labeling antibodies with biotin and ... quantitation of the target molecule. In ... use only the antigen-binding (Fab) portion ...
...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Request Info...
Biology Products: